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Site-directed mutagenesis was employed to examine the function of two highly conserved residues. Tyr-37 and Arg-41, of human EGF (hEGF) 
in receptor binding. Both a conservative change to phenylalanine and a semi-conservative change to histidine at position 37 yield proteins with 
receptor affinity similar to wild-type hEGF. A non-conservative change to alanine results in a molecule with about 40% of the receptor affinity, 
indicating that an aromatic residue is not essential at this position. Both conservative (to lysine) and non-conservative (to alanine) substitutions 
at position 41 drastically reduced receptor binding to ~0.5% of the wild-type activity. ID-NMR data indicate that the replacement of Arg-41 by 
lysine does not significantly alter the native protein conformation. Thus. Arg-41 may be directly involved in ligand-receptor interaction, whereas 
the side chain of Tyr-37, although possibly Important structurally, is not essential for receptor binding. 
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1. INTRODUCTION 
EGF is a 6-kDa (53 residues) polypeptide with three 
internal disulfide bonds. Upon binding to its specific 
cell surface receptor, EGF elicits multiple molecular 
and cellular responses which ultimately lead to increas- 
ed DNA synthesis and cell proliferation (see [l-3] for 
recent reviews). 
Recently, there has been increased interest in identi- 
fying residues in EGF that function in receptor recogni- 
tion and binding (see [3] for a review). In previous 
reports from our laboratory ([4,5]; Campion, S.R., 
Matsunami, R.K., Engler, D.A. and Niyogi, S.K., 
manuscript submitted for publication) we described 
site-directed mutagenesis studies of hEGF aimed at 
identifying the residues involved in receptor recogni- 
tion, based on functional assays of ligand binding and 
activation of the protein-tyrosine kinase activity of the 
EGF receptor. The residues chosen for mutagenesis 
were based largely on considerations of their species in- 
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variance and recently described solution structures of 
hEGF [6] and mEGF [7-91. Our studies involved 
residues in different regions of the EGF molecule and 
showed the importance of Tyr-22, Ile-23, Leu-26, 
Tyr-29 and Leu-47 in receptor binding. Residues in the 
third disulfide loop region distal to the amino terminal 
end were not included in those studies. 
The third loop of EGF is formed as a consequence of 
the disulfide bridge between Cys-33 and Cys-42 (see 
Fig. 1) and comprises the most highly conserved region 
in the EGF-like family of molecules [lo]. Of the five 
residues that are consistently conserved in this loop of 
those EGF-like species that have actually been shown to 
bind to the EGF receptor, two are the cysteines that 
define the loop and a third is the glycine at position 39 
that is presumed to be conserved for energetic reasons 
du.e to its location in a short left-handed helical confor- 
mation [S]. The remaining two residues that are ab- 
solutely conserved are Tyr-37 and Arg41. We have 
combined structural information, based on NMR 
measurements, with functional activity of several site- 
directed mutants at positions 37 and 41 of hEGF to 
clarify the roles of these residues in receptor binding. 
2. MATERIALS AND METHODS 
2. I. Materials 
Materials have already been described [4] 
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Fig. 1. Schematic representation of secondary structural features of 
indicated. 
hEGF. Solid lines indicate disulfide bridges, and hydrogen bonds are 
indicated by dashed lines. Dashed circles indicate residues with no 
rigid structural characteristics (as determined by NMR). The various 
single amino acid substitutions performed at each site are also 
2.2. Oligonucleotide-directed mutagenesis 
EGF mutants were generated by oligonucleotide-directed 
mutagenesis using protocols described earlier [4,11]. The hEGFgene 
used as a template was cloned into M13mp19 as described earlier [4]. 
All engineered mutations as well as the absence of any undesired 
genetic alterations were confirmed by sequencing [12] the entire 
hEGF gene. 
2.3. Expression and purification of wild type and mutant hEGF 
proteins 
Expression of wild type and mutant proteins was achieved with 
modifications to the protocol already described [4]. It was found that 
the addition of 1-5 pg/ml of chloramphenicol to the growth medium 
during the induction phase greatly increased EGF yields (Engler, 
D.A., PhD thesis; Engler and Niyogi, manuscript in preparation); 
therefore this was used routinely. Purification was carried out as 
previously described [4]. 
2.4. EGF recepfor binding assay 
Specific binding of EGF proteins to the EGF receptor was 
measured by radioreceptor competition [13] using purified membrane 
fractions from the human epidermoid carcinoma cell line, A431. 
A431 cells were grown in Dulbecco’s modified Eagle’s medium sup- 
plemented with 10% fetal calf serum. A431 membranes were isolated 
as described [14]. [“‘I]hEGF was prepared by the chloramine-T 
method [Is] to an average specific activity of approx. 
150000 cpm/pmol. 
2.5. NA4R spectroscopy of proteins 
Purified protein samples were dialyzed against distilled deionized 
water at pH 6.5 and lyophilized to dryness. Samples were resuspend- 
ed in DrO to a concentration of 1 mM and the reading of the pH 
meter (without correction for isotope effects) adjusted to 7.2 f 0.1 
with 0.1 M NaOH in DzO. Samples were allowed to exchange all 
labile protons for deuterons for a minimum of 3 h before 
measurements were recorded. ‘H-NMR spectra were recorded at 
30°C on a Varian VXR 500 spectrometer. 
3. RESULTS 
3.1. Mutant verification 
Homogeneity of each EGF protein was confirmed by 
analytical reverse-phase chromatography and amino 
acid composition analysis. The latter measurements 
verified the expected amino acid change for each mu- 
tant protein. 
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Fig. 2. Competition binding curves of 13 nM [lZ’l]hEGF vs wild-type 
and arginine-41 analogs. 
3.2. Radioreceptor competition assays 
Fig. 2 shows the competition binding curves for wild- 
type hEGF in relation to the singly substituted mutants 
of arginine 41; namely, Arg4’-+Lys and 
Arg”‘-Ala. Similarly, Fig. 3 shows the relationship 
of competition binding curves for wild-type hEGF and 
the singly substituted mutants of tyrosine 37; namely, 
Tyr37*Phe, Tyr3’---,His and Tyr3’-+Ala. The con- 
centration of competing species that gave a 50% inhibi- 
tion of binding of [‘251]hEGF to the receptor (IC50) was 
estimated graphically from the curve for each mutant. 
This concentration is listed in Table I for each mutant 
along with its relative receptor affinity as compared to 
that of wild-type which was set at 100%. The results 
show that substitutions, even a non-conservative one, 
at position 37 are tolerated quite well, while both 
substitutions at position 41 drastically reduce the recep- 
tor affinity. However, even the poorest binders could 
displace [“‘I]hEGF at sufficiently high concentrations, 
indicating their specific interactions with the EGF 
receptor. 
3.3. NMR spectra of proteins 
Aromatic residues are spread throughout the hEGF 
molecule in its 3-dimensional structure [6] and the 
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Fig. 3. Competition binding curves of 13 nM [“‘l]hEGF vs wild-type 
and tyrosine-37 analogs. 
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Table I 
Comparison of ICse values and relative receptor binding affinities 
EGF species I’& 01M) Relative binding 
affinity 
(070 of wild type) 
Wild type 13.0 x 1o-3 100 
Tyr3’-Phe 10.3 x lo-) 126 
Tyr”*His 17.5 x 1o-3 74 
Tyr”---‘Ala 33.0 x 1o-3 39 
Arg4’-+Lys 3.0 0.43 
Arg4’dAla 26.2 0.05 
IC5a is the concentration of the competitor giving 50% inhibition of 
binding of ‘Z51-labeled wild-type EGF to the receptor (see Figs 2 and 
3). Relative binding affinity = I&, (wild type)/ICsa (mutant) x 100%. 
resonance frequencies of these aromatic ring protons 
are sensitive to molecular conformation and solvent ac- 
cessibility. Accordingly, comparisons of the aromatic 
resonance frequencies of wild-type and mutant proteins 
provide a convenient approach for distinguishing cor- 
rectly from incorrectly folded mutants [ 161. The NMR 
data were obtained for protein solutions at neutral pH. 
Proteins which exhibit native-like lD-NMR spectra 
may still have some localized minor structural pertur- 
bations which will be characterized only by more detail- 
ed 2D-NMR studies. We have been very careful to 
avoid interpreting chemical shift changes accompany- 
ing mutations involving aromatic ring substitutions, 
since alterations in aromatic ‘ring-current’ effects can 
result in conformation-independent changes in 
chemical shifts. Thus, no serious attempt was made to 
interpret changes observed in the NMR spectra of the 
Tyr-37 mutants (data not shown). 
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Fig, 4. Comparison of aromatic and downfield C% spectral regions 
from 500 MHz 1D ‘H-NMR spectra of (A) wild-type EGF, (B) 
Arg4’*Lys EGF, (C) Arg4’-Ala EGF at neutral pH. Conditions 
were as described in section 2. 
For mutants involving Arg-41, the aromatic and 
downfield CW regions of the 1D ‘H-NMR spectra, 
from 5.0 to 8.5 ppm, are used for comparison of struc- 
tural integrity. These spectra are shown in Fig. 4. The 
lD-NMR spectra of the wild-type (Fig. 4A) and the 
Lys-41 mutant (Fig. 4B) display very similar profiles 
with very few peaks exhibiting significant chemical 
shifts (2 50 ppb) indicating no major structural changes 
in the global chain fold of this particular mutant with 
respect to the wild-type native conformation. The 
Ala-41 mutant (Fig. 4C) displays a somewhat altered 
NMR profile with respect to wild-type in that there are 
several peaks with small chemical shift differences. 
Some peak broadening can also be observed in the spec- 
trum of this particular mutant. 
4. DISCUSSION 
Either a conservative or non-conservative substitu- 
tion at the arginine 41 site results in an EGF molecule 
with very poor receptor affinity. 1D ‘H-NMR 
measurements indicate no major structural alterations 
in either of the mutants. The qualitative difference in 
the spectra for the Lys-41 and Ala-41 mutants is consis- 
tent with our finding that notwithstanding their ex- 
tremely poor affinities for the EGF receptor, the Ala-41 
mutant has an affinity approximately &fold lower than 
that of the Lys-41 mutant. Our results indicate that the 
guanidino group of arginine 41 may be involved in 
receptor interaction. 
The tyrosine residue at position 37 seems to play a 
different role in the EGF molecule. A very conservative 
change at this site, namely to phenylalanine, produced 
a mutant that retained the aromatic character of the 
original phenol ring but lost the polar -OH group. 
This mutant has a somewhat higher affinity for the 
EGF receptor than wild-type. When position 37 was 
mutated to histidine, in which the imidazole ring retains 
some of the aromatic character and the approximate 
size of the tyrosine but again lacks the polar -OH 
group, the binding affinity dropped to 74% of that of 
wild type. Replacement of the tyrosine side chain with 
the small hydrophobic alanine side chain only 
moderately decreased the receptor binding affinity, to 
about 40% of wild-type. These results indicate that a 
tyrosine at position 37 is not essential for interaction 
with the receptor. However, the nature of the aromatic 
residue at position 37 does influence, to some small 
degree, the binding affinity for the receptor. Precise 
characterization of a possible structural role of tyrosine 
37 in EGF must await detailed 2D-NMR studies of 
these mutants. 
That tyrosine 37 may play a role in maintaining some 
structural feature(s) common to all EGF-like species is 
indicated by the fact that chemical functionality of an 
aromatic residue at position 37 remains uncompromis- 
ed even in that group of EGF-like species that contain 
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EGF-like domains and are thought to adopt similar 
conformations to EGF, but do not bind to the EGF 
receptor [3,10]. Chemical functionality of the arginine 
at position 41, however, is not maintained in all EGF- 
like species, rather only in those proteins, including 
TGF-cu, that bind to the EGF receptor [3,10]. This sup- 
ports our observation of the essentiality of Arg-41 of 
hEGF in receptor binding. It should be noted also that 
the replacement of the analogous residue (Arg-42) of 
hTGF-Lu with lysine reduced receptor binding to < 1 .O% 
of wild-type [ 17). Although NMR data were lacking for 
the Lys-42 hTGF-cu mutant, the disulfide arrangement 
was shown to be identical to that of wild-type [17]. 
This similarity between EGF and TGF-cx in receptor 
binding does not completely extend to Tyr-37 (Tyr-38 
in hTGF+). Although a conservative change to 
phenylalanine at position 38 also produced a mutant 
hTGF-cu with a somewhat higher receptor binding af- 
finity, the Ala-38 hTGF-cu mutant (unlike our Ala-37 
hEGF mutant) was only approx. 3% as active as wild- 
type [ 181. Lazar et al. [ 191 also postulated the essentiali- 
ty of an aromatic residue at position 38 of TGF-cu, us- 
ing partially purified mutant analogs, but reported a 
His-38 mutant with negligible activity. Thus, although 
an aromatic residue at position 38 may be essential for 
the biological activity of TGF-a, tyrosine 37 in hEGF 
is not essential for receptor binding. 
EGF and TGF-cu may recognize and/or bind to the 
EGF receptor in a dissimilar manner as indicated by re- 
cent studies [20] showing that a monoclonal antibody 
to the EGF receptor had only small effects on the bin- 
ding of EGF to the EGF receptor but had large effects 
on the binding of TGF-Q to the EGF receptor. Dif- 
ferences between these two different ligands in their 
mode of binding to their common receptor, as ex- 
emplified by the different roles of Tyr-37 (in EGF) and 
Tyr-38 (in TGF-a), as discussed above, may account 
for the differences in the ultimate biological responses 
elicited by these distinct growth factors [21]. 
The present study suggests an essential role of 
Arg-41, and/or atoms nearby in the 3-dimensional 
structure, in interactions with the EGF receptor. 
Similar studies suggest that Leu-47, and/or residues 
nearby in the 3-dimensional structure, also play some 
role in interactions of mEGF [16] and hEGF ([22]; Mat- 
sunami, R.K., Stevens, A., Montelione, G.T. and 
Niyogi, S.K., manuscript in preparation) with the 
receptor. Examinations of the solution structures of 
both hEGF and mEGF reveal that these two side chains 
(Arg-41 and Leu-47) are located on one face of the pro- 
tein molecule. Other side chains contributing to this 
face include Tyr-13, Leu-15, His-16, Gln-43, Tyr-44, 
Arg-45 and Asp-46 (Montelione, G.T., unpublished 
results). Structure-function studies, in progress, are 
aimed at characterizing the roles these spatially adja- 
cent residues play in forming the receptor recognition 
site of EGF. 
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